New Delhi: The Ministry of External Affairs said on Thursday (April 7, 2022) that the suspension of the supply of Covaxin on “process and facility upgrade” requirements by the World Health Organization (WHO) through UN procurement agencies will not affect the travel of those Will not. Those who have taken the Kovid-19 vaccine.
Responding to a question, Ministry of External Affairs Spokesperson Arindam Bagchi said that in the context of his travels, the vaccine is recognized under the emergency use list of WHO and has already been accepted by various countries.
“I think there has been a statement issued by Bharat Biotech as well as WHO, which have been very clear in emphasizing that the vaccine is safe, it is effective. Its effectiveness is not in question.” ,
“There is something about process issues that are working out between the company and the WHO. You have to ask them about the details.”
Covaxin, an indigenous covid-19 vaccine , manufactured by Hyderabad-based Bharat Biotech. Bagchi also said, “I don’t think it is a cause for concern” as India has mutual recognition of its vaccination certificate arrangements with various countries.
Earlier on Saturday, World Health Organization said that it has suspended the supply of Covaxin through UN agencies in response to the need for process and facility upgrades to address the recently identified GMP (Good Manufacturing Practice) deficiencies.
However, the UN body has clarified that there are no issues related to the safety and efficacy of the vaccine.